Status: Recruiting
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
Participants needed: 5
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Takara Bio Inc.Updated: Feb 18, 2026Locations: 2
Eligibility criteria
≥ 18 years of age [+11]
Patients with the following conditions are excluded from the study; Unstable ang... [+12]